Compare BOKF & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOKF | ALKS |
|---|---|---|
| Founded | 1910 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 7.5B |
| IPO Year | 2007 | 2012 |
| Metric | BOKF | ALKS |
|---|---|---|
| Price | $134.53 | $48.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 14 |
| Target Price | ★ $133.67 | $43.43 |
| AVG Volume (30 Days) | 249.2K | ★ 2.2M |
| Earning Date | 04-20-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | ★ 12.65 | N/A |
| EPS | ★ 2.58 | N/A |
| Revenue | N/A | ★ $1,475,899,000.00 |
| Revenue This Year | $6.56 | $24.26 |
| Revenue Next Year | $5.22 | $4.47 |
| P/E Ratio | $51.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $96.89 | $25.17 |
| 52 Week High | $139.73 | $46.63 |
| Indicator | BOKF | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 58.41 | 78.79 |
| Support Level | $129.49 | $27.65 |
| Resistance Level | $136.59 | N/A |
| Average True Range (ATR) | 2.54 | 1.66 |
| MACD | 0.46 | 0.17 |
| Stochastic Oscillator | 84.74 | 99.29 |
BOK Financial Corp is a financial institution based in Oklahoma that offers a broad range of nationally competitive financial products and services. The company operates through three main segments: Commercial Banking, Consumer Banking, and Wealth Management. Commercial Banking provides lending, treasury and cash management, and risk management services, and includes the TransFund EFT network. Consumer Banking focuses on retail lending, deposit services, and mortgage loan origination and servicing. Wealth Management engages mainly in brokerage and trading activities, particularly in U.S. government agency mortgage-backed securities and related derivatives. The company generates the majority of its revenue from the Commercial Banking segment.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.